Axogen, Inc.
AXGN Nasdaq· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 26, 2026
$38.02
KIRA · Stoqly’s AI analyst, in plain words
- Axogen, Inc. had $225M of revenue in fiscal 2025, up 20.2% on the year before. Over five years, revenue changed +14.9% a year on average.
- Its operating margin was −3.5%, down 1.7 pts: of every 100 in sales, about −3 is left after running the business.
- Axogen, Inc. lost $15.7M in fiscal 2025.
- Free cash flow was −$2.9M in fiscal 2025, −1.3% of revenue.
- Axogen, Inc. owes $6.9M more than it holds in cash.
Market cap
$2.0B
P/E
—
Revenue
$225M
Net income
−$15.7M
Free cash flow
−$2.9M
Operating margin
−3.5%
Axogen, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.2%
Yes. Sales grew 20.2% last year.
Does it make a profit?
−7.0%
No. It lost money last year.
Does profit turn into cash?
−1.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Axogen, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Axogen, Inc.
- CIK
- 0000805928
Axogen, Inc. · AXGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $127M | $139M | $159M | $187M | $225M |
| Revenue growth | 13.4% | 8.8% | 14.7% | 17.8% | 20.2% |
| Gross margin | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Operating margin | −20.0% | −21.4% | −13.5% | −1.8% | −3.5% |
| Net income | −$27.0M | −$28.9M | −$21.7M | −$10.0M | −$15.7M |
| Net margin | −21.2% | −20.9% | −13.7% | −5.3% | −7.0% |
| Diluted EPS | −$0.65 | −$0.69 | −$0.51 | −$0.23 | −$0.34 |
| Cash | |||||
| Cash from operations | −$13.4M | −$16.1M | −$5.7M | $4.5M | $0.8M |
| Capital expenditure | $27.8M | $20.1M | $13.9M | $3.1M | $3.7M |
| Free cash flow | −$41.2M | −$36.1M | −$19.6M | $1.4M | −$2.9M |
| FCF margin | −32.4% | −26.1% | −12.3% | 0.8% | −1.3% |
| Share count change | 3.1% | 2.1% | 1.9% | 3.2% | 4.1% |
| Debt and strength | |||||
| Cash and short-term investments | $84.1M | $48.8M | $31.0M | $33.5M | $41.5M |
| Debt incl. finance leases | $44.8M | $45.7M | $46.6M | $47.5M | $48.4M |
| Shareholders' equity | $113M | $101M | $95.7M | $104M | $129M |
| Net debt / EBITDA | — | — | — | 4.4x | — |
| Current ratio | 5.2x | 4.1x | 2.9x | 3.2x | 5.1x |
| Interest coverage | −18.7x | −47.6x | −7.6x | −0.4x | −1.0x |
| Returns and quality | |||||
| Return on capital | −27.4% | −24.0% | −15.2% | −2.2% | −4.6% |
| Return on equity | −22.9% | −27.1% | −22.1% | −10.0% | −13.5% |
| Return on tangible equity | −24.6% | −29.7% | −23.8% | −10.1% | −12.9% |
| Piotroski F-score | 3 | 2 | 3 | 6 | 5 |
| Altman Z'' | 0.0 | −1.7 | −2.5 | −1.5 | −0.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$19.3M
12 insiders
Of sales under plans
36%
$6.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Axogen, Inc. · AXGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $38.02 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0000805928). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.